Treatment Efficiency and Problems of Local Control in Localized Bladder/Prostate Rhabdomyosarcoma
Cancer Research Journal
Volume 7, Issue 2, June 2019, Pages: 33-38
Received: Feb. 19, 2019;
Accepted: Mar. 22, 2019;
Published: Apr. 18, 2019
Views 604 Downloads 82
Hanafy Hafez, Pediatric Oncology, National Cancer Institute (NCI), Cairo University, Cairo, Egypt
Enas El Nadi, Pediatric Oncology Department, Beni Suef University, Beni Suef, Egypt
Alaa Younes, Surgical Oncology, National Cancer Institute, Cairo University, Cairo, Egypt
Gehad Ahmed, Surgery Department, Faculty of Medicine, Helwan University, Helwan, Egypt
Mohamed Saad Zaghloul, Radiation Oncology, National Cancer Institute (NCI), Cairo University, Cairo, Egypt
Hala Taha, Surgical Pathology, National Cancer Institute (NCI), Cairo University, Cairo, Egypt
Rania Labib, Clinical Research Department, Children Cancer Hospital Egypt, Cairo, Egypt
Sayed Abdelhamid Fadel, Pediatric Oncology, National Cancer Institute (NCI), Cairo University, Cairo, Egypt
Soha Ahmed, Department of Clinical Oncology, Aswan University, CCHE, Cairo, Egypt
Objectives: To assess the treatment efficiency, outcome and factors affecting the local control of localized bladder/prostate RMS. Patients and methods: Retrospective analysis of 54 patients with localized bladder/prostate RMS treated at Children Cancer Hospital, Egypt between August 2007 and Jan 2017. All patients were treated according to Intergroup Rhabdomyosarcoma Study (IRS -V) and subsequent Children’s Oncology Group COG guidelines. Results: The median age at diagnosis was 3.28 years (range 0.4–13.6). Fifty-one patients (94%) underwent initial biopsy. Complete surgical resection (primary or delayed) was performed in 7 patients (13%). Local control started before/at week 12 in 29 patients (61.7%). Local control methods were: Radiotherapy in 43 patients (79.2%), radiotherapy with surgery in 4 patients (9%), surgery in 1 patient and four patients did not receive local control. With a median follow up of 38.12 months, the 5-year failure-free survival (FFS) and overall (OS) of the whole patients were 60.4 ± 14.5% and 75.4 ± 14.1% respectively. A better 5-year FFS was experienced by those who had early local control (79.2 ± 17% vs. 43.8 ± 25% p= 0.005). Conclusions: Timing of local control and local radiotherapy is crucial and shouldn’t be delayed waiting for further response to the systemic chemotherapy.
Enas El Nadi,
Mohamed Saad Zaghloul,
Sayed Abdelhamid Fadel,
Treatment Efficiency and Problems of Local Control in Localized Bladder/Prostate Rhabdomyosarcoma, Cancer Research Journal.
Vol. 7, No. 2,
2019, pp. 33-38.
Spunt SL, Sweeney TA, Hudson MM, Billups CA, Krasin MJ, Hester AL. Late effects of pelvic rhabdomyosarcoma and its treatment in female survivors. J Clin Oncol 2005; 23:7143–51. doi:10.1200/JCO.2005.12.096.
Lott S, Lopez-Beltran A, Montironi R, MacLennan GT, Cheng L. Soft tissue tumors of the urinary bladder. Hum Pathol 2007; 38:963–77. doi:10.1016/j.humpath.2007.03.016.
Hays DM, Raney RB, Wharam MD, Wiener E, Lobe TE, Andrassy RJ, et al. Children with vesical rhabdomyosarcoma (RMS) treated by partial cystectomy with neoadjuvant or adjuvant chemotherapy, with or without radiotherapy. A report from the Intergroup Rhabdomyosarcoma Study (IRS) Committee. J Pediatr Hematol Oncol 1995; 17:46–52.
Pappo AS, Shapiro DN, Crist WM, Maurer HM. Biology and therapy of pediatric rhabdomyosarcoma. J Clin Oncol 1995; 13:2123–39. doi:10.1200/JCO.19184.108.40.2063.
Meza JL, Anderson J, Pappo AS, Meyer WH, Children’s Oncology Group. Analysis of Prognostic Factors in Patients With Nonmetastatic Rhabdomyosarcoma Treated on Intergroup Rhabdomyosarcoma Studies III and IV: The Children’s Oncology Group. J Clin Oncol 2006; 24:3844–51. doi:10.1200/JCO.2005.05.3801.
Hays DM. Bladder/prostate rhabdomyosarcoma: results of the multi-institutional trials of the Intergroup Rhabdomyosarcoma Study. Semin Surg Oncol n.d.; 9:520–3.
Arndt C, Rodeberg D, Breitfeld PP, Raney RB, Ullrich F, Donaldson S. Does bladder preservation (as a surgical principle) lead to retaining bladder function in bladder/prostate rhabdomyosarcoma? Results from intergroup rhabdomyosarcoma study iv. J Urol 2004; 171:2396–403.
Fryer CJ. Pelvic rhabdomyosarcoma: paying the price of bladder preservation. Lancet (London, England) 1995; 345:141–2.
Stevens MCG, Rey A, Bouvet N, Ellershaw C, Flamant F, Habrand JL, et al. Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology--SIOP Malignant Mesenchymal Tumor 89. J Clin Oncol 2005; 23:2618–28. doi:10.1200/JCO.2005.08.130.
Seitz G, Dantonello TM, Int-Veen C, Blumenstock G, Godzinski J, Klingebiel T, et al. Treatment efficiency, outcome and surgical treatment problems in patients suffering from localized embryonal bladder/prostate rhabdomyosarcoma: A report from the cooperative soft tissue sarcoma trial CWS-96. Pediatr Blood Cancer 2011; 56:718–24. doi:10.1002/pbc.22950.
Ferrer FA, Isakoff M, Koyle MA. Bladder/prostate rhabdomyosarcoma: past, present and future. J Urol 2006; 176:1283–91. doi:10.1016/j.juro.2006.06.019.
Malempati S, Hawkins DS. Rhabdomyosarcoma: review of the Children’s Oncology Group (COG) Soft-Tissue Sarcoma Committee experience and rationale for current COG studies. Pediatr Blood Cancer 2012; 59:5–10. doi:10.1002/pbc.24118.
Stevens MCG. Treatment for childhood rhabdomyosarcoma: the cost of cure. Lancet Oncol 2005; 6:77–84. doi: 10.1016/S1470-2045(05)01733-X.
Jenney M, Oberlin O, Audry G, Stevens MCG, Rey A, Merks JHM, et al. Conservative approach in localised rhabdomyosarcoma of the bladder and prostate: results from International Society of Paediatric Oncology (SIOP) studies: malignant mesenchymal tumour (MMT) 84, 89 and 95. Pediatr Blood Cancer 2014; 61:217–22. doi:10.1002/pbc.24727.
Martelli H, Haie-Meder C, Branchereau S, Franchi-Abella S, Ghigna M-R, Dumas I, et al. Conservative surgery plus brachytherapy treatment for boys with prostate and/or bladder neck rhabdomyosarcoma: a single team experience. J Pediatr Surg 2009; 44:190–6. doi:10.1016/J.JPEDSURG.2008.10.040.
Crist WM, Anderson JR, Meza JL, Fryer C, Raney RB, Ruymann FB, et al. Intergroup Rhabdomyosarcoma Study-IV: Results for Patients With Nonmetastatic Disease. J Clin Oncol 2001; 19:3091–102. doi:10.1200/JCO.2001.19.12.3091.
Baker KS, Anderson JR, Link MP, Grier HE, Qualman SJ, Maurer HM, et al. Benefit of Intensified Therapy for Patients With Local or Regional Embryonal Rhabdomyosarcoma: Results From the Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol 2000; 18:2427–34. doi:10.1200/JCO.2000.18.12.2427.
Oberlin O, Rey A, Sanchez de Toledo J, Martelli H, Jenney MEM, Scopinaro M, et al. Randomized Comparison of Intensified Six-Drug Versus Standard Three-Drug Chemotherapy for High-Risk Nonmetastatic Rhabdomyosarcoma and Other Chemotherapy-Sensitive Childhood Soft Tissue Sarcomas: Long-Term Results From the International Society of Pediatr. J Clin Oncol 2012; 30:2457–65. doi:10.1200/JCO.2011.40.3287.
Jenney M, Oberlin O, Audry G, Stevens MCG, Rey A, Merks JHM, et al. No Title 2014; 61. doi:10.1002/pbc.24727.
Raney B, Anderson J, Jenney M, Arndt C, Brecht I, Carli M, et al. Late effects in 164 patients with rhabdomyosarcoma of the bladder/prostate region: a report from the international workshop. J Urol 2006; 176:2190-4; discussion 2194-5. doi:10.1016/j.juro.2006.07.064.
Modritz D, Ladenstein R, Pötschger U, Amman G, Dieckmann K, Horcher E, et al. Treatment for soft tissue sarcoma in childhood and adolescence. Austrian results within the CWS 96 study. Wien Klin Wochenschr 2005; 117:196–209.
Michalski JM, Meza J, Breneman JC, Wolden SL, Laurie F, Jodoin MA, et al. Influence of radiation therapy parameters on outcome in children treated with radiation therapy for localized parameningeal rhabdomyosarcoma in Intergroup Rhabdomyosarcoma Study Group trials II through IV. Int J Radiat Oncol 2004; 59:1027–38. doi:10.1016/J.IJROBP.2004.02.064.